Name<\/span><\/b><\/p>\n<\/td>\n
For<\/span><\/b><\/p>\n<\/td>\n
Against<\/span><\/b><\/p>\n<\/td>\n
Broker Non-Votes<\/span><\/b><\/p>\n<\/td>\n<\/tr>\n \nNathalie Bernier<\/p>\n<\/td>\n \n344,100,848<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n124,733<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,315,925<\/p>\n<\/td>\n<\/tr>\n \nRichard U. De Schutter<\/p>\n<\/td>\n \n344,094,979<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n130,602<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,315,925<\/p>\n<\/td>\n<\/tr>\n \nGary Hu<\/p>\n<\/td>\n \n344,016,782<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n208,799<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,315,925<\/p>\n<\/td>\n<\/tr>\n \nBrett Icahn<\/p>\n<\/td>\n \n344,072,707<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n152,874<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,315,925<\/p>\n<\/td>\n<\/tr>\n \nSarah B. Kavanagh<\/p>\n<\/td>\n \n343,989,666<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n235,915<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,315,925<\/p>\n<\/td>\n<\/tr>\n \nJohn A. Paulson<\/p>\n<\/td>\n \n344,095,439<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n130,142<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,315,925<\/p>\n<\/td>\n<\/tr>\n \nRussel C. Robertson<\/p>\n<\/td>\n \n344,098,056<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n127,525<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,315,925<\/p>\n<\/td>\n<\/tr>\n \nThomas W. Ross, Sr.<\/p>\n<\/td>\n \n340,211,351<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n4,014,230<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,315,925<\/p>\n<\/td>\n<\/tr>\n \nBrenton L. Saunders<\/p>\n<\/td>\n \n342,408,245<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,817,336<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,315,925<\/p>\n<\/td>\n<\/tr>\n \nAndrew C. von Eschenbach, M.D.<\/p>\n<\/td>\n \n343,985,915<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n239,666<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,315,925<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nAt the Annual Meeting, shareholders also approved, in a non-binding advisory vote, the compensation of the Company\u2019s named executive officers and the frequency of future advisory votes on named executive officer compensation being one year, approved an amendment and restatement of the Company\u2019s 2022 Omnibus Incentive Plan (the \u201cPlan\u201d) to increase the number of common shares authorized for issuance thereunder, and appointed PricewaterhouseCoopers LLP as the Company\u2019s independent registered public accounting firm until the close of the Company’s 2024 annual meeting of shareholders.<\/p>\n \nFor the purposes of Toronto Stock Exchange (\u201cTSX\u201d) approval with respect to the Plan, the Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible inter-listed issuers on a recognized exchange, such as the NYSE.<\/p>\n \nThe final vote tabulation on all matters voted on at the Annual Meeting will be filed with the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company’s SEDAR profile and on the Company\u2019s website at www.bausch.com<\/a>.<\/p>\n About Bausch + Lomb \u00a9 2023 Bausch & Lomb Incorporated or its affiliates.<\/i><\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230425005469\/en\/<\/a><\/span><\/p>\n Investors: \nAllison Ryan Media: KEYWORDS:<\/b> United States North America Canada<\/p>\n INDUSTRY KEYWORDS:<\/b> Pharmaceutical Health Optical<\/p>\n\n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n
\n
<\/b>Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world \u2013 from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com<\/a> and connect with us on Twitter<\/a>, LinkedIn<\/a>, Facebook<\/a> and Instagram<\/a>.<\/p>\n<\/p>\n
\n<\/b>
Arthur Shannon
\n
arthur.shannon@bausch.com<\/a><\/p>\n
\n
<\/b>allison.ryan@bausch.com
\n<\/a>
(877) 354-3705 (toll free)
\n
(908) 927-0735<\/p>\n
\n<\/b>
Lainie Keller
\n
lainie.keller@bausch.com
\n<\/a>
(908) 927-1198<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230425005469\/en\/1668940\/3\/Bausch_%2B_Lomb_logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n